Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 7.01 (Regulation FD Disclosure). XP-8121 program overview publicly furnished under Regulation FD on September 9, 2026.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- XP-8121 program overview publicly furnished under Regulation FD on September 9, 2026
- Exhibit 99.2 contains the substantive program details and is incorporated into the filing
- Disclosure may affect valuation based on XP-8121’s development progress and commercial potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.